Breast cancer (BC) is the most common diagnosed cancer type worldwide. Among breast cancer subtypes, Triple Negative Breast Cancer (TNBC) stands out due to its heightened aggressiveness, marked by a high incidence of metastasis, relapse, and patient mortality. TNBC poses a unique challenge as it exhibits significant genetic diversity and lacks molecular targets like the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Consequently, traditional targeted therapies are ineffective against TNBC. KRAS gene plays a central role in cell signaling pathways controlling cellular growth, differentiation and survival. KRAS is the most frequently mutated oncogene in humans.